Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cardinal Health Inc filings on SEC EDGAR ↗
Cardinal Health held its 2026 Annual Meeting of Shareholders on November 12, 2026, where shareholders elected 11 directors to the board. Additionally, shareholders approved the executive compensation plan (say-on-pay) and ratified the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending June 30, 2027.
This document is an exhibit from Cardinal Health's 10-Q filing outlining forward-looking risk factors, including competitive pricing pressures, generic pharmaceutical demand, and potential impacts from international tariffs. It also highlights risks related to opioid litigation settlements, regulatory compliance, and supply chain disruptions for medical products.
Cardinal Health reported Q1 fiscal 2027 revenue of $67.5 billion, a 5% increase year-over-year, driven by brand and specialty pharmaceutical sales. Non-GAAP diluted EPS rose 28% to $3.26, leading the company to raise its full-year fiscal 2027 non-GAAP EPS guidance. The company also completed a $500 million share repurchase program during the quarter.
Term
Q1 2027
“Our results reflect a strong start to fiscal 2027 and demonstrate consistent execution against our strategic priorities. We continue to benefit from focused investments, disciplined operations and the strength of our diversified portfolio. Given this quarter's strong performance and our updated expectations for the remainder of the year, we are raising our fiscal 2027 non-GAAP EPS outlook.”
Cardinal Health entered into a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 2032. In connection with the extension, the company reaffirmed its fiscal year 2027 non-GAAP EPS guidance of $12.40 to $12.60 and its long-term growth targets.